[Treatment of the choroidal neovascular membrane by ranibizumab (Lucentis): a case report].
A 73-year-old woman presented with a best-corrected visual acuity of 6/9 in her right eye and 6/36 in her left eye. Fundus examination revealed signs of age related macular degeneration in both eyes. In her right eye it was just dry form of the disease, in left one an elevated lesion associated with retinal cystoid edema was detected. Ocular coherence tomography and fluorescein angiogram confirmed a subfoveal occult choroidal neovascular membrane. We decided for intravitreal ranibizumab (Lucentis, 0.5 mg) treatment. One month after first injection, best-corrected visual acuity improved to 6/15 in her left eye. After six months, best-corrected visual acuity further improved to 6/12, with complete resolution subretinal fluid on ocular coherence tomography.
Univerzita Karlova v Praze, Ocní klinika 1. LF UK a UVN, 1 lékarská fakulta, Praha, Czech Republic. pavel.nemec@uvn.cz
P
P
Nemec
Z
Z
Benesová
L
L
Hejsek
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D000069579:Ranibizumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab